Plain-English translation of NCT03998319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After you receive emergency angioplasty for a heart attack, doctors will measure blood flow resistance in your heart artery. If that measurement is high, you may be randomly assigned to receive either tenecteplase (a clot-dissolving medication) or a placebo (salt water) injected directly into your heart artery. The study is testing whether this medication can improve heart function and reduce damage after a heart attack.
Even after emergency angioplasty to open a blocked artery during a heart attack, some patients have poor blood flow in the heart tissue itself. This trial is testing whether the medication can improve that blood flow and help the heart recover better.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive your emergency angioplasty as normal. After that procedure, a special measurement will be taken of blood flow in your heart artery. If this measurement indicates you need the study medication, you will randomly receive either the clot-dissolving medication or placebo injected into your heart artery over 3 minutes. You will have heart imaging at discharge (3–7 days later) and at 6 months, with clinic visits and blood work at multiple timepoints over 2 years to track your recovery.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Australia